Teriparatide, backwards

Parathyroid hormone is the body’s fastest defense against low blood calcium. Let the calcium level dip and within minutes PTH is released, pulling calcium out of bone, reclaiming it in the kidney, and switching on vitamin D to absorb more from food. It is, in its day job, a hormone that spends the skeleton to keep the blood supplied — and when it runs unchecked, that is exactly what it does.

In primary hyperparathyroidism, a parathyroid tumor secretes PTH continuously, and the classic consequence is a skeleton slowly mined for calcium: thinned bone, in severe cases the cavities and fractures of osteitis fibrosa. For most of the twentieth century this was the whole reputation of PTH where bone was concerned — a catabolic hormone, the agent of a bone-wasting disease. Which is why the drug built from it is one of the most counterintuitive objects in endocrinology. Bullish on the science, sceptical on the easy story.

Teriparatide is parathyroid hormone — specifically its active business end, the first 34 residues, PTH(1-34) — given as a once-daily injection. And it does the opposite of what its parent hormone’s reputation predicts: it builds bone. That makes it categorically different from the older osteoporosis drugs. Bisphosphonates and the rest are antiresorptive — they slow the loss of bone. Teriparatide is anabolic; it lays down new bone that was not there before, the first drug to do so.

This was not a theoretical nicety. In the pivotal trial, daily teriparatide cut the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis (Neer et al., NEJM, 2001). The hormone of a bone-dissolving disease had become the first bone-building medicine. The entire resolution of that paradox is a single variable — and it is one this site has met before, in another axis.

Bone does not read whether PTH is present. It reads how long it stays. A brief daily spike and a permanently elevated level are, to the skeleton, two different signals — and they drive opposite programs through the very same PTH1 receptor. This is the same counterintuitive rule that governs the reproductive axis, where pulsatile GnRH switches the system on and continuous GnRH switches it off. In bone, the clock decides between building and breaking.

The mechanism splits cleanly. A short pulse of PTH switches on the osteoblast — the bone-forming cell — faster than it switches on resorption, inducing the formation program (immediate-early genes, a drop in the bone-formation brake sclerostin) and opening what the field calls the anabolic window: a span in which formation outruns breakdown. A continuously high level does the reverse. It keeps driving the osteoclast side, raising RANKL and lowering osteoprotegerin until resorption dominates and the skeleton is spent (Silva & Bilezikian, Curr Opin Pharmacol, 2015). Same receptor, same hormone, opposite verdict — written by the shape of the exposure in time.

The rule is not unique to PTH. Its sibling, PTH-related protein, shares PTH’s N-terminus and acts on the same PTH1 receptor — and it obeys the same frequency law. Given intermittently as the analog abaloparatide, PTHrP is anabolic, and in its phase 3 trial it reduced new vertebral fractures much as teriparatide does (Miller et al., JAMA, 2016).

And the catabolic face is there too, in the most literal way. When a tumor secretes PTHrP continuously into the blood, the result is the leading cause of hypercalcemia of malignancy — the skeleton stripped of calcium by exactly the mechanism continuous PTH1-receptor signaling predicts. One receptor, two ligands, and in both the identical rule: a pulse builds bone, a plateau dissolves it. The receptor is not reading which molecule arrived; it is reading how long the message lasts.

The anabolic window is not permanent, and that shapes how the drug is used. As treatment continues, resorption gradually catches up with formation; the net building advantage narrows, and bone gains plateau. So anabolic therapy is deliberately time-limited — a course of roughly two years — after which an antiresorptive is given to lock in the bone that was built, because the gains erode if nothing holds them. The logic even extends to combinations: pairing teriparatide with a potent antiresorptive from the start can blunt the anabolic effect, since the formation program leans on some of the turnover the antiresorptive is suppressing.

Two footnotes complete the honest picture. A rat study found bone tumors at high lifetime exposure, which shaped the drug’s labeling and the limit on treatment duration. And calcitonin, the hormone that formally opposes PTH by lowering calcium, turns out to play only a minor role in adult human bone — a reminder that the interesting lever in this axis was never a second hormone, but the timing of the first one.

Step back and PTH joins a small, revealing club: hormones whose meaning lives in time rather than concentration. The reproductive axis reads the frequency of GnRH; the skeleton reads the duration of PTH. In both, the same molecule flips a system’s behavior end to end depending only on whether it arrives as a pulse or a plateau, and in both the most useful drugs are the ones that write to that rhythm deliberately. Teriparatide is what it looks like to take a hormone with a fearsome catabolic reputation and, by changing nothing but the clock, turn it into the first drug that builds the very tissue its parent was known for dissolving.

• PTH is catabolic when it never switches off. Continuous excess, as in hyperparathyroidism, mines the skeleton for calcium — the hormone's historical reputation in bone.
• Teriparatide is PTH(1-34) given once daily. A single daily pulse makes it the first anabolic osteoporosis drug — it builds new bone, where antiresorptives only slow loss. It cut fractures in its pivotal trial.
• Duration decides, through one receptor. A brief spike drives the osteoblast formation program (↓sclerostin) and opens an 'anabolic window'; a sustained level drives osteoclasts (↑RANKL, ↓OPG). Same PTH1R, opposite outcome.
• PTHrP obeys the same law. Intermittent PTHrP (abaloparatide) builds bone and cut vertebral fractures; continuous tumor-secreted PTHrP causes hypercalcemia of malignancy. One rule, two ligands.
• The window closes, so the course is finite. Resorption catches up over ~2 years; anabolic therapy is time-limited and followed by an antiresorptive to lock in the gains. The drug is the schedule, not a new molecule.